# Study of Epacadostat (INCB024360) Alone and In Combination With Pembrolizumab (MK-3475) With Chemotherapy and Pembrolizumab Without Chemotherapy in Participants With Advanced Solid Tumors (MK-3475-434)

> **NCT02862457** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 34 (actual)

## Conditions studied

- Neoplasms
- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Epacadostat 25 mg
- **DRUG:** Epacadostat 100 mg
- **BIOLOGICAL:** pembrolizumab 200 mg
- **DRUG:** Cisplatin 75 mg/m^2
- **DRUG:** Carboplatin Area Under the Curve (AUC) 5
- **DRUG:** Pemetrexed 500 mg/m^2
- **DRUG:** Paclitaxel 200 mg/m^2
- **DRUG:** Carboplatin AUC 6

## Key facts

- **NCT ID:** NCT02862457
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-23
- **Primary completion:** 2020-11-20
- **Final completion:** 2020-11-20
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2022-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02862457

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02862457, "Study of Epacadostat (INCB024360) Alone and In Combination With Pembrolizumab (MK-3475) With Chemotherapy and Pembrolizumab Without Chemotherapy in Participants With Advanced Solid Tumors (MK-3475-434)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02862457. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*